Search results for "VIRUS"

showing 10 items of 5024 documents

Natural and adoptive T-cell immunity against herpes family viruses after allogeneic hematopoietic stem cell transplantation.

2011

Reactivated infections with herpes family-related cytomegalovirus, Epstein–Barr virus and varicella zoster virus are serious and sometimes life-threatening complications for patients undergoing allogeneic hematopoietic stem cell transplantation. The pathogenesis of these infections critically involves the slow and inefficient recovery of antiviral T-cell immunity after transplantation. Although efficient drugs to decrease viral load during this vulnerable period have been developed, long-term control of herpes viruses and protection from associated diseases require the sufficient reconstitution of virus-specific memory T cells. To heal the deficiency by immunotherapeutic means, numerous re…

Adoptive cell transfervirusesmedicine.medical_treatmentT-LymphocytesImmunologyHematopoietic stem cell transplantationBiologyAdaptive Immunitymedicine.disease_causeVirusImmunitymedicineImmunology and AllergyAnimalsHumansVaricella zoster virusHematopoietic Stem Cell TransplantationHerpesviridae InfectionsVirologyEpstein–Barr virusImmunity InnateTransplantationOncologyImmunologyImmunizationViral loadImmunotherapy
researchProduct

COVID-19 and periodontitis: reflecting on a possible association

2021

AbstractRecent studies have demonstrated a relationship between the severe clinical course of COVID-19 and other chronic diseases such as: cardiovascular disease, hypertension, diabetes mellitus, obesity and chronic renal disease. It may be possible to extend this association to a common and chronic oral disease in adults: periodontitis. Alternatively, the latter could be simply related to the systemic chronic diseases cited above, as already observed in the non-COVID-19 literature. In order to provide an overview and their opinion, the authors in this perspective article will report and discuss the most recent references of interest relating to COVID-19 and periodontitis pathophysiology. W…

Adult0301 basic medicineSpecialties of internal medicineDiseaseBioinformatics03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicineHumansObesityPeriodontitisInterleukin 6General DentistryPeriodontitisIL-6biologySARS-CoV-2business.industryCOVID-19030206 dentistryHypothesismedicine.diseaseChronic periodontitisObesityPathophysiologyCoronavirusIL-17030104 developmental biologyRC581-951OtorhinolaryngologyChronic Diseasebiology.proteinNeurology (clinical)Interleukin 17businessHead & Face Medicine
researchProduct

A Trial of Lopinavir–Ritonavir in Covid-19

2020

Adult2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralLopinavir/ritonavirPharmacologyLopinavirBetacoronavirusmedicineHumansPandemicsRitonavirBetacoronaviruPandemicCoronavirus InfectionSARS-CoV-2business.industryCOVID-19LopinavirGeneral MedicineCOVID-19 Drug TreatmentRitonavirCoronavirus InfectionsbusinessCoronavirus InfectionsHumanmedicine.drugNew England Journal of Medicine
researchProduct

Impact of coronavirus disease 2019 (COVID-19) outbreak on radiology research: An Italian survey

2021

Abstract Purpose To understand how COVID-19 pandemic has changed radiology research in Italy. Methods A questionnaire (n = 19 questions) was sent to all members of the Italian Society of Radiology two months after the first Italian national lockdown was lifted. Results A total of 327 Italian radiologists took part in the survey (mean age: 49 ± 12 years). After national lockdown, the working-flow came back to normal in the vast majority of cases (285/327, 87.2%). Participants reported that a total of 462 radiological trials were recruiting patients at their institutions prior to COVID-19 outbreak, of which 332 (71.9%) were stopped during the emergency. On the other hand, 252 radiological tri…

Adult2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ArticleTrialSurveys and QuestionnairesPandemicSurveys and QuestionnaireHumansMedicineRadiology Nuclear Medicine and imagingPandemicsPractice Policy & EducationPandemicSARS-CoV-2business.industryResearchOutbreakMean ageMiddle AgedItalyRadiology Nuclear Medicine and imagingRadiologistRadiological weaponCommunicable Disease ControlRadiologyRadiologyCovid-19businessHumanClinical Imaging
researchProduct

Human immunodeficiency virus infection mimics autoimmune hepatitis--a case report.

1988

AdultAcquired Immunodeficiency SyndromeHepatitis Viral Humanbusiness.industryHuman immunodeficiency virus (HIV)AIDS SerodiagnosisHIVGeneral MedicineAutoimmune hepatitismedicine.disease_causemedicine.diseaseVirologyMolecular medicineHuman geneticsAutoimmune DiseasesDiagnosis DifferentialLiverDrug DiscoverymedicineMolecular MedicineHumansFemalebusinessGenetics (clinical)Klinische Wochenschrift
researchProduct

[The distribution of hepatitis C virus (HCV) genotypes in the drug-dependent population in Palermo].

1999

AdultAdolescentGenotypeUrban PopulationSubstance-Related Disordershepatitis C antibodyHepacivirusHepatitis C AntibodiesSettore MED/42 - Igiene Generale E Applicatavirus RNAHumansRNA ViralSicilyRetrospective StudiesAnnali di igiene : medicina preventiva e di comunita
researchProduct

Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.

1988

Four-hundred and seventeen patients undergoing open-heart surgery were followed for more than 9 months after transfusion. All 2270 blood units transfused had alanine aminotransferase levels less than or equal to 30 U/l. Blood units positive for antibodies to hepatitis B core antigen (anti-HBc) were more frequently associated with recipient hepatitis non-A, non-B (HNANB) (13.7%) than anti-HBc-negative units (4.2%) (p less than 0.001). The frequency of HNANB among recipients of at least 1 anti-HBc-positive blood unit (8/79, 10.1%) was fivefold greater than among recipients of exclusively anti-HBc-negative blood units (7/338, 2.1%) (p less than 0.01). In this study the exclusion of donors posi…

AdultAdolescentHepatitis Viral HumanImmunologyBlood DonorsAntigenImmunology and AllergyMedicineHumansAlanine aminotransferaseHepatitis B AntibodiesAgedHepatitisbiologybusiness.industryIncidence (epidemiology)virus diseasesTransfusion ReactionAlanine TransaminaseHematologyMiddle Agedmedicine.diseaseHepatitis B Core AntigensHepatitis Cdigestive system diseasesImmunologybiology.proteinBlood unitsAntibodybusinessDonor screeningHepatitis b coreTransfusion
researchProduct

Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus.

2018

OBJECTIVE: To optimize the management of patients with chronic hepatitis C virus (HCV). MATERIALS AND METHODS: We developed two questionnaires to determine Italian healthcare professionals’ opinions on the overall management of HCV chronic liver disease and the use of direct-acting antivirals (DAAs) in the treatment of HCV. A Delphi consensus method using the RAND/UCLA appropriateness method was used to determine opinions of an expert panel (EP) of specialists. RESULTS: Overall 443 physicians from 167 Italian centres completed the two questionnaires. The EP confirmed the importance of collaboration with general practitioners (GPs) and HCV testing in high-risk groups, but did not agree on tr…

AdultAged 80 and overLiver CirrhosisMaleConsensusGenotypedelphi methodhepatitis c virus; direct-acting antivirals; delphi method; consensus; adult; aged 80 and over; antiviral agents; consensus; elasticity imaging techniques; female; genotype; hepacivirus; hepatitis c chronic; humans; liver cirrhosis; male; middle aged; surveys and questionnairesHepacivirushepatitis c virusHepatitis C ChronicMiddle AgedAntiviral AgentschronicagedSurveys and QuestionnairesHCV80 and overElasticity Imaging TechniquesHumansFemalehepatitis cdirect-acting antiviralsEuropean review for medical and pharmacological sciences
researchProduct

SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway

2022

Objectives To assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence. Methods This is the first part of a prospective multi-centre cohort study. Participants The study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months aft…

AdultAged 80 and overMaleMultidisciplinaryNorwaySARS-CoV-2COVID-19Middle AgedAntibodies ViralCohort StudiesYoung AdultSpike Glycoprotein CoronavirusHumansFemaleVDP::Medisinske Fag: 700Prospective StudiesAged
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct